^
    11d
    UC-GIG-2515: Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients withnhigh risk of recurrence of their disease. (2025-523913-27-00)
    P2/3, N=272, Not yet recruiting, Unicancer
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • levoleucovorin calcium
    14d
    MOUNTAINEER-03: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=400, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Jul 2029 --> Jul 2030 | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium
    23d
    A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure (clinicaltrials.gov)
    P3, N=398, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    5-fluorouracil • capecitabine • oxaliplatin • trastuzumab brengitecan (BL-M07D1) • levoleucovorin calcium
    1m
    KEYNOTE 975: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) (clinicaltrials.gov)
    P3, N=703, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Jun 2026 | Trial primary completion date: Feb 2027 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • oxaliplatin • levoleucovorin calcium
    1m
    A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) (clinicaltrials.gov)
    P3, N=538, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    5-fluorouracil • capecitabine • oxaliplatin • izalontamab brengitecan (BL-B01D1) • levoleucovorin calcium
    2ms
    Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P2, N=41, Completed, Institut de Recherches Internationales Servier | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Sep 2025
    Trial completion • Trial completion date
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • levoleucovorin calcium
    2ms
    New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, The First Hospital of Jilin University
    New P2 trial
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • levoleucovorin calcium
    2ms
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (clinicaltrials.gov)
    P3, N=864, Active, not recruiting, Merck Sharp & Dohme LLC | N=136 --> 864
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium
    2ms
    Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov)
    P2, N=80, Recruiting, Southwest Autism Research & Resource Center | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    leucovorin calcium • levoleucovorin calcium
    2ms
    Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Southwest Autism Research & Resource Center | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date
    |
    leucovorin calcium • levoleucovorin calcium
    2ms
    Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, Southwest Autism Research & Resource Center | Trial completion date: Dec 2025 --> Jul 2026
    Trial completion date
    |
    leucovorin calcium • levoleucovorin calcium
    2ms
    Panitumumab-4004: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=757, Active, not recruiting, Takeda | Trial completion date: Mar 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • levoleucovorin calcium